[1] WANG HuixiaDUAN Yuhong SONG Zongliang ZHANG Xiaoke LI Jiarui PENG Hao,.Re Evaluation of Traditional Chinese Patent Medicines and Simple Preparations in the Treatment of Diabetes Nephropathy [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2024, (05): 14-23. [doi: 10.13424/j.cnki.jsctcm.2024.05.003]
Re Evaluation of Traditional Chinese Patent Medicines and Simple Preparations in the Treatment of Diabetes Nephropathy
- Article number:
- 2096-1340(2024)05-0014-10
- Keywords:
- Key words： Diabetes nephropathy; Traditional Chinese patent medicines and simple preparations; AMSTAR 2; PRISMA; Systematic evaluation and re evaluation
- ZTFLH:
- R587.1
- Code:
- A
- Abstract:
- Abstract： Objective To evaluate the methodological quality and reporting quality of systematic reviews (SRs) of traditional Chinese patent medicines and simple preparations in the treatment of diabetes nephropathy (DKD),evaluate the efficacy and adverse reactions of traditional Chinese patent medicines and simple preparations in the treatment of diabetes nephropathy,and provide evidence-based medical evidence for its clinical application.Methods The PubMed,Cochrane Library,Embase,CBM,CNKI,VIP and Wanfang Data databases were retrieved.Two researchers independently screened the literature,extracted the data,and included SRs of traditional Chinese patent medicines and simple preparations in the treatment of DKD.AMSTAR 2 (a measurement tool to assess systematic reviews-2) and PRISMA (reporting items for systematic reviews and meta analysis) were used to evaluate the methodological quality and reporting quality of SRs,and the Meta analysis results were presented in tables.Results A total of 28 SRs were included,and the AMSTAR2 evaluation results showed that 18 SRs were of medium quality,7 SRs were of low quality,and 3 SRs were of extremely low quality;The PRISMA evaluation results are: 20 SRs reports are relatively complete,7 SRs reports have certain defects,and 1 SRs report has serious defects.Conclusion The existing evidence shows that traditional Chinese patent medicines and simple preparations is superior to conventional western medicine in improving the effective rate,improving laboratory indicators and reducing adverse reactions in the treatment of DKD,but there are some defects in the methodological quality and reporting quality of SRs,which should be treated cautiously.Therefore,in order to better guide clinical practice,the methodological and reporting quality of relevant SRs need to be further improved in the future.
References:
［1］中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南（2021年版）［J］.中华糖尿病杂志,2021,13(8):762-784.
［2］RUIZ-ORTEGA M,RODRIGUES-DIEZ RR,LAVOZ C,et al.Special Issue “Diabetic Nephropathy:Diagnosis,Prevention and Treatment”［J］.J Clin Med,2020,9(3):813.
［3］HOU JH,ZHU HX,ZHOU ML,et al.Changes in the spectrum of kidney diseases:an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China［J］.Kidney Dis (Basel),2018,4(1):10-19.
［4］中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南［J］.中华肾脏病杂志,2021,37(3):255-304.
［5］杜丽沙,马鸿杰.中医药治疗糖尿病肾病研究状况及趋势的可视化分析［J］.湖南中医杂志，2021,37(12):129-134,142.
［6］高岩,宋宗良,段玉红,等.百令胶囊辅助治疗糖尿病肾病的Meta分析［J］.药物评价研究,2021,44(1):161-169.
［7］张婧,李靖,张海力,等.尿毒清颗粒联合血管紧张素系统阻滞剂治疗糖尿病肾病的Meta分析［J］.世界中医药,2021,16(2):274-283.
［8］龚丽,黄寅銮,谢韶妍,等.百令胶囊联合缬沙坦治疗糖尿病肾病临床疗效及安全性的Meta分析［J］.广州中医药大学学报,2021,38(5):1061-1066.
［9］魏远清,陈静.丹参注射液联合前列地尔治疗糖尿病肾病临床疗效及安全性Meta分析［J］.新中医,2020,52(16):16-20.
［10］黄玲珑,王冠东,张捷平,等.济生肾气丸用于糖尿病肾病临床疗效的系统评价［J］.中国医院用药评价与分析,2020,20(5):586-592.
［11］连心逸,柳红芳,王向明,等.金水宝胶囊联合血管紧张素转换酶抑制剂治疗糖尿病肾病系统评价［J］.中国中医药信息杂志,2020,27(9):103-107.
［12］张俊华,商洪才,张伯礼.系统评价和Meta分析质量的评价方法［J］.中西医结合学报,2008,6(4):337-340.
［13］葛龙,潘蓓,潘佳雪,等.解读AMSTAR-2——基于随机和(或)非随机对照试验系统评价的质量评价工具［J］.中国药物评价,2017,34(5):334-338.
［14］高亚,刘明,杨珂璐,等.系统评价报告规范：PRISMA 2020与PRISMA 2009的对比分析与实例解读［J］.中国循证医学杂志,2021,21(5):606-616.
［15］SHENG XH,YANG D,CHENG D S,et al.Efficacy and safety of Bailing capsules in the treatment of type 2 diabetic nephropathy:a meta-analysis［J］.Ann Palliat Med，2020，9(6):3885-3898.
［16］TAN YM,HU J,WU Q,et al.Fufang Xueshuantong for Diabetic Kidney Disease:A Systematic Review and Meta-Analysis［J］.Evidence-Based Complement Alternat Med，2020（12）:9326948.
［17］黄雅兰,黄国东,蔡林坤,等.百令胶囊联合RAAS阻断剂治疗早期糖尿病肾病疗效和安全性的系统评价［J］.中华中医药学刊,2019,37(6):1290-1297.
［18］甘文渊.肾炎康复片治疗糖尿病肾病的Meta分析及系统评价［J］.时珍国医国药,2018,29(4):1014-1016.
［19］QIANG L,LI CL,CHEN WW,et al.Clinical efficacy of Jin Shui Bao Capsules Combined with Angiotensin Receptor Blockers in Patients with Early Diabetic Nephropathy:A Meta-Analysis of Randomized Controlled Trials［J］.Evid Based Complement Alternat Med，2018:6806943.
［20］王荣,张莲,艾金伟,等.肾炎康复片联合西医常规疗法治疗糖尿病肾病有效性的Meta分析［J］.世界中医药,2017,12(1):180-185,190.
［21］黄秋明,孙洁雨.复方血栓通胶囊联合血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂治疗早期糖尿病肾病疗效的系统评价［J］.中国医院用药评价与分析,2016,16(8):1081-1087.
［22］许帅,邓小凤,冯秋苑,等.复方血栓通胶囊治疗糖尿病肾病Ⅲ期的系统评价［J］.辽宁中医杂志,2016,43(11):2249-2253.
［23］邓小凤,许帅,朱章志.参芪降糖颗粒治疗糖尿病肾病Ⅲ期的系统评价［J］.内蒙古中医药,2016,35(7):1-3.
［24］LAN L,WANG QH,YI YX,et al.Liuwei Dihuang Pills Enhance the Effect of Western Medicine in Treating Diabetic Nephropathy:A Meta-Analysis of Randomized Controlled Trials［J］.Evid Based Complement Alternat Med，2016:1509063.
［25］段蓉,李正翔.金水宝联合血管紧张素受体阻滞剂治疗糖尿病肾病的Meta分析［J］.药物评价研究,2015,38(1):78-84.
［26］王海焱,刘铜华.参芪降糖颗粒治疗糖尿病肾病Meta分析［J］.世界科学技术-中医药现代化,2015,17(12):2608-2613.
［27］刘丽,詹钊,韩冰冰.丹参注射液治疗糖尿病肾病的系统评价［J］.山西医药杂志,2014,43(13):1549-1554.
［28］季欣星,徐军建,唐晓.系统评价百令胶囊对糖尿病肾病患者肾功能水平的影响［J］.湖北中医杂志,2014,36(12):3-5.
［29］唐榕,陈路佳,黄玲,等.百令胶囊联合常规治疗早期糖尿病肾病的系统评价［J］.中国药业,2013,22(14):19-23.
［30］李会芳,程生辉,赵换.丹参注射液辅助治疗糖尿病肾病有效性及安全性的系统评价［J］.中国实验方剂学杂志,2013,19(6):353-358.
［31］黄毅岚,杨虹,汪世梅.百令胶囊治疗早期糖尿病肾病的系统评价［J］.中国药业,2012,21(20):18-21.
［32］张煜敏,杨丽萍,沈波.金水宝胶囊治疗糖尿病肾病的系统评价［J］.现代中西医结合杂志,2012,21(23)：2509-2512.
［33］毛家玺,程铭,汤晓静.金水宝治疗糖尿病肾病的系统评价［J］.中国中西医结合肾病志,2012,13(6):526-530.
［34］贺小华,葛振远.百令胶囊防治糖尿病肾病疗效观察的Meta分析［J］.临床荟萃,2012,27(13):1164-1166.
［35］龙轩,王锋,黄昶荃.通心络胶囊治疗糖尿病肾病的系统评价［J］.中国循证医学杂志,2010,10(1):73-80.
［36］王锋,吴红梅.血脂康治疗糖尿病肾病的系统评价［J］.中国循证医学杂志,2009,9(1):63-70.
Memo
基金项目：陕西省自然科学基础研究计划项目（2022JM-494）;陕西省中医药管理局科研计划项目（2019-GJ-QT002）